Royalty Payable	9 Months Ended
Sep. 30, 2018
Payables and Accruals [Abstract]
Royalty Payable	Royalty Payable The Company entered into various agreements and subsequently received funding from investors for use by the Company for the research and development of its OORT Product. In exchange for this funding, the Company agreed to provide investors with interest in the OORT Net Profit generated from its OORT Product in perpetuity. As of December 31, 2017, the Company determined an OORT Net Profit as a result of NARCAN sales by Adapt and recorded a royalty payable of $1.4 million. As of September 30, 2018, the Company has a royalty payable of $800 thousand to all of the Net Profit Partners.

Royalty Payable

9 Months Ended

Sep. 30, 2018

The Company entered into various agreements and subsequently received funding from investors for use by the Company for the research and development of its OORT Product. In exchange for this funding, the Company agreed to provide investors with interest in the OORT Net Profit generated from its OORT Product in perpetuity. As of December 31, 2017, the Company determined an OORT Net Profit as a result of NARCAN sales by Adapt and recorded a royalty payable of $1.4 million. As of September 30, 2018, the Company has a royalty payable of $800 thousand to all of the Net Profit Partners.